Oral administration of myricetin significantly reduces Fe 2+ levels in the substantia nigra of PD rats, inhibits neuronal ferroptosis, decreases ROS production, downregulates malondialdehyde (MDA) and -synuclein (-Syn) expression, elevates GSH levels, and ameliorates motor deficits
They also reduce inappropriate glucagon signaling, which helps decrease excess glucose production
Its broad range of effects suggests potential applications for tissue regeneration, gut health, neurological conditions, cardiovascular protection, and chronic pain management
Compounding itself is not new or inherently unsafe
Reduced risk factors for diabetes, high cholesterol, and hypertension
Certain health conditions such as intestinal or stomach problems, poor nutrition, cancer, HIV, pregnancy, old age, veganism, and alcoholism can cause vitamin B12 deficiency